TuHURA Biosciences (HURA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$9.2M

Net income growth (year over year)

+3.16%

Net margin

—

Return on equity

−161.43%

EPS (trailing twelve months)

−$0.54

Book value per share

$0.29

P/E (trailing twelve months)

—

Price to book

6.30

Debt to assets

41.72%

Payout ratio

—

Dividend yield

—

Company profile

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

• How do I buy stock in TuHURA Biosciences (HURA)?

  HURA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.